System and method for controlling pulsed beam dedicated to multi-gantry-structured carbon nanotube x-ray generator in order to treat degenerative brain diseases

Abstract

The present invention relates to a pulsed beam control system for treating degenerative brain diseases and, to a technique for precisely controlling irradiation intensity, pulse width, period, irradiation angle and the like of radiation in order to provide patient-customized radiation therapy. More specifically, the present invention includes the system which concentrates radiation at a lesion site and which can minimize radiation exposure to adjacent normal tissue through real-time dose monitoring and distance measurement.

Description

Pulse beam control system and method dedicated to a carbon nanotube X-ray generator with a multi-gantry structure for the treatment of degenerative brain diseases

[0001] The present invention relates to a pulse beam control system for treating degenerative brain diseases, and more particularly, to a technology that provides an optimized radiation irradiation angle and energy to a lesion area of ​​a patient by utilizing a multi-gantry structure, and maximizes safety and treatment effectiveness through real-time dose monitoring and feedback control.

[0002] 1. This result is the result of the 2023 Hongneung Specialized Growth Support Project [H-(Reverse) Train], which was carried out with the support of the Research and Development Special Zone Promotion Foundation and the funding from the Ministry of Science and ICT in 2023. "Research Project Title: Development of a Brain Drug Delivery System Using Carbon Nanotube-Based Low-Dose Ionizing Radiation" 2. This result is the result of the Hongneung Specialized Growth Support Project (H-Bridge), which was carried out with the support of the Research and Development Special Zone Promotion Foundation and the funding from the Ministry of Science and ICT in 2023. "Research Project Title: Development of a Medical Device for Opening the Blood-Brain Barrier Using Carbon Nanotube-Based Low-Dose Ionizing Radiation"

[0003] Degenerative brain diseases (such as Alzheimer's and Parkinson's) are caused by neuroinflammation and pathological changes. Primary treatments include drug therapy and non-invasive techniques. Recent studies have demonstrated the effectiveness of low-dose radiation therapy (LDRT) in suppressing neuroinflammation, reducing pathological markers, and protecting neurons, and efforts are underway to apply it to treatment. While continuous beam LDRT provides treatment stability by continuously delivering a constant dose, it has limitations in minimizing tissue damage and finely controlling biological responses. Therefore, pulsed beam irradiation technology is gaining attention. Pulsed beam control technology is developing to minimize tissue damage while delivering high therapeutic efficacy to lesions by precisely adjusting pulse width and cycle time. Furthermore, multi-gantry structures capable of delivering radiation from multiple angles and real-time dose control technology are being actively introduced to enhance the precision and efficiency of radiation therapy.

[0004] Existing technologies lack this control, making them unable to enhance therapeutic efficacy and potentially causing unnecessary radiation exposure, potentially leading to tissue damage and nerve cell damage. If the pulse width and frequency of radiation administered cannot be precisely adjusted to suit the patient's condition, treatment effectiveness is reduced and the risk of side effects increases. Furthermore, their lack of real-time control limits the ability to immediately detect and correct over- or under-dosage situations during radiation therapy. Furthermore, they cannot adapt to changes in radiation angle and distance due to patient movement or changes in body shape.

[0005] Systems that apply pulsed beam irradiation technology are attracting attention as a new approach to simultaneously secure the safety and effectiveness of radiation therapy by strengthening the functions of precise radiation control, real-time monitoring, and integrated data management to solve these problems.

[0006] The purpose of the present invention is to maximize the treatment effect by measuring and adjusting the radiation dose for each patient in real time during radiation treatment.

[0007] The purpose of the present invention is to uniformly irradiate radiation to a lesion area at various angles by utilizing a multi-gantry structure.

[0008] The purpose of the present invention is to provide customized treatment by optimizing radiation parameters such as pulse number, cycle, and energy intensity according to the individual characteristics of a patient.

[0009] The purpose of the present invention is to systematically store and analyze data generated during radiation treatment and reflect it in subsequent treatment plans.

[0010] A pulse beam control system for treating a degenerative brain disease according to an embodiment may include a pulse beam information setting unit that sets pulse beam information including a pulse number, a pulse cycle, a pulse beam irradiation angle, or pulse beam energy according to the characteristics of a patient and the purpose of treatment, a beam control unit that individually controls in series or in parallel at least one of a tube voltage, a tube current, a pulse width, an irradiation time, or an irradiation point of a multi-port X-ray generator based on the set pulse beam information, a dose monitoring unit that monitors and stores patient-tailored dose information corresponding to a generated pulse beam in real time, and a data management unit that manages and outputs patient treatment data based on the monitored data.

[0011] The pulse beam information setting unit according to one embodiment can automatically calculate and set the pulse beam information based on treatment plan data transmitted from an external system.

[0012] The beam control unit according to one embodiment can provide an optimized irradiation angle and energy distribution to a body part of a patient through a multi-gantry structure.

[0013] According to one embodiment, the dose monitoring unit can collect data by communicating with the Dose Rate Monitoring System and the SSD Monitoring System to measure real-time dose information of a patient.

[0014] According to one embodiment, the data management unit can analyze the dose data collected from the dose monitoring unit, evaluate the treatment effect for each patient, and control the output.

[0015] According to one embodiment, the data management unit may configure a database to store patient treatment data and dose data and reuse the data as data required for follow-up treatment.

[0016] The beam control unit according to one embodiment can synchronize the irradiation time of pulse beams generated from each X-ray generator and irradiate them in parallel or serially.

[0017] The dose monitoring unit according to one embodiment may use a feedback control algorithm to optimize the dose and energy intensity of the irradiated pulse beam for each patient.

[0018] A pulse beam control method for treating a degenerative brain disease according to an embodiment may include a step of setting a pulse number, a pulse cycle, a pulse beam irradiation angle, and a pulse beam energy according to the characteristics of a patient and the purpose of treatment, a step of individually controlling a tube voltage, a tube current, a pulse width, an irradiation time, and an irradiation point of a multi-port X-ray generator in series or in parallel based on the set information, a step of monitoring and storing patient-tailored dose information corresponding to the controlled pulse beam in real time, and a step of analyzing and recording the treatment effect of the patient based on the stored data.

[0019] The step of setting the pulse number, pulse period, pulse beam irradiation angle, and pulse beam energy according to one embodiment may include a step of automatically setting them based on patient data received from an external system.

[0020] The control step of the multi-port X-ray generator according to one embodiment may include a step of providing an optimized irradiation angle and energy distribution to a body part of a patient using a multi-gantry structure.

[0021] A pulse beam control method for treating a degenerative brain disease according to one embodiment may further include a step of adjusting a set dose and energy intensity using a feedback control algorithm based on dose data measured in real time during the process of controlling the pulse beam.

[0022] In one embodiment, real-time dose monitoring and feedback control can maximize therapeutic effects while minimizing radiation exposure.

[0023] According to one embodiment, a multi-gantry structure can be used to uniformly distribute radiation even to complex lesion structures.

[0024] In one embodiment, patient-tailored radiation therapy is possible through precise control of pulse beam parameters.

[0025] In one embodiment, stored treatment data can be used to analyze long-term treatment effects and develop improved treatment strategies.

[0026] FIG. 1 is a diagram illustrating a pulse beam control system for treating degenerative brain diseases according to one embodiment.

[0027] Figure 2a is a diagram showing the results showing that there is no statistical significance in the effect of reducing Aβ plaques when continuous beam (KLDR) is applied.

[0028] Figure 2b is a diagram showing the results showing that the effect of reducing Aβ plaques is statistically significant when pulsed beam (PKLDR) is applied.

[0029] Figure 3 is a diagram showing that in a live imaging experiment, the expression level of M2-type microglia (CD206, anti-inflammatory action) significantly increases when pulsed beam (PKLDR) is applied.

[0030] Figure 4 is a diagram showing that, in a live imaging experiment, the expression levels of disease markers Aβ42 and tau are significantly reduced when a pulsed beam (PKLDR) is applied.

[0031] Figure 5 is a diagram showing that inflammation markers (TNF-α, IL-1β), recovery genes (RSPO1), and dopamine neuron activity markers (VMAT2, DAT) significantly increase when pulsed beam (PKLDR) is applied.

[0032] Figure 6 is a drawing showing a pulse beam precisely controlled by the present invention.

[0033] Figure 7 is a drawing showing an application field of the present invention.

[0034] Figure 8 is a drawing explaining an operating system according to an embodiment.

[0035] FIG. 9 is a diagram illustrating an operation method of a pulse beam control system for treating degenerative brain diseases according to one embodiment.

[0036] Specific structural or functional descriptions of embodiments according to the concept of the present invention disclosed in this specification are merely illustrative for the purpose of explaining embodiments according to the concept of the present invention, and embodiments according to the concept of the present invention may be implemented in various forms and are not limited to the embodiments described in this specification.

[0037] Embodiments according to the concept of the present invention may have various modifications and take various forms, and thus, embodiments are illustrated in the drawings and described in detail in this specification. However, this is not intended to limit embodiments according to the concept of the present invention to specific disclosed forms, but rather includes modifications, equivalents, or alternatives that fall within the spirit and technical scope of the present invention.

[0038] While terms such as "first" or "second" may be used to describe various components, these components should not be limited by these terms. These terms are intended solely to distinguish one component from another. For example, a first component may be referred to as a "second component," and similarly, a second component may also be referred to as a "first component," without departing from the scope of the invention.

[0039] When a component is referred to as being "connected" or "connected" to another component, it should be understood that it may be directly connected or connected to that other component, but that there may be other components in between. Conversely, when a component is referred to as being "directly connected" or "directly connected" to another component, it should be understood that there are no other components in between. Expressions that describe relationships between components, such as "between," "immediately between," or "directly adjacent to," should be interpreted similarly.

[0040] The terminology used herein is for the purpose of describing specific embodiments only and is not intended to limit the present invention. The singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, it should be understood that the terms "comprises" or "has" are intended to specify the presence of a described feature, number, step, operation, component, part, or combination thereof, but do not preclude the possibility of the presence or addition of one or more other features, numbers, steps, operations, components, parts, or combinations thereof.

[0041] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and will not be interpreted in an idealized or overly formal sense unless explicitly defined herein.

[0042]

[0043] Hereinafter, embodiments will be described in detail with reference to the attached drawings. However, the scope of the patent application is not limited or restricted by these embodiments. The same reference numerals in each drawing represent the same components.

[0044] FIG. 1 is a drawing illustrating a pulse beam control system (100) for treating degenerative brain diseases according to one embodiment.

[0045] Figure 1 is a block diagram illustrating the components and interactions of a pulse beam control system (100) for treating degenerative brain diseases. It integrates the setup, control, monitoring, and data management of pulse beams for patient-tailored treatment. All components are organically connected and operate around a central control unit (150), and the roles and detailed functions of each component are as follows.

[0046] The pulse beam information setting unit (110) sets pulse beam information according to the patient's treatment plan and purpose.

[0047] A pulse beam information setting unit (110) according to one embodiment sets pulse beam information including pulse count, pulse cycle, pulse beam irradiation angle, or pulse beam energy according to the patient's characteristics and treatment purpose. The pulse count is increased when stimulation is required depending on the characteristics of the treatment area, or decreased for sensitive tissues to minimize side effects.

[0048] Pulsed light therapy can be used for long-duration treatments to promote tissue recovery, or for short-duration treatments to provide sustained stimulation. Pulsed beam angles optimize the direction of radiation delivery to the target area, maximizing radiation effectiveness by precisely targeting specific brain regions, for example.

[0049] Pulse beam energy is set to high energy for deep tissue treatment and low energy for surface treatment. According to one embodiment, the pulse beam information setting unit (110) automatically calculates pulse beam information using treatment plan data provided from an external system and generates optimal settings based on the patient's MRI data.

[0050] A beam control unit (120) according to an embodiment individually controls at least one of the tube voltage, tube current, pulse width, irradiation time, or irradiation point of a multi-port X-ray generator in series or in parallel based on the set pulse beam information. In particular, the parameters of the X-ray generator are adjusted based on the set pulse beam information.

[0051] The tube voltage determines the energy of the beam, with high voltage used for deep tissue treatment and low voltage used for superficial treatment.

[0052] Tube current controls the beam volume, while pulse width adjusts the total radiation dose. Synchronized irradiation points allow for parallel or serial delivery of radiation from multiple ports, and the multi-gantry architecture provides optimized irradiation angles and energy distribution based on the patient's anatomy and lesion location.

[0053] A beam control unit (120) according to one embodiment precisely controls radiation energy and direction for patient-tailored treatment, and operates in real time in conjunction with a control unit (150).

[0054] A beam control unit (120) according to one embodiment can provide an optimized irradiation angle and energy distribution to a patient's body part through a multi-gantry structure.

[0055] A beam control unit (120) according to one embodiment can synchronize the irradiation time of pulse beams generated from each X-ray generator and irradiate them in parallel or serially.

[0056] A dose monitoring unit (130) according to one embodiment monitors and stores patient-specific dose information corresponding to the generated pulse beam in real time. Furthermore, it can collect data by communicating with a Dose Rate Monitoring System and an SSD Monitoring System to measure the patient's real-time dose information.

[0057] A dose monitoring unit (130) according to one embodiment monitors and analyzes dose data delivered to a patient during radiation irradiation in real time. The Dose Rate Monitoring System measures the instantaneous rate of radiation dose, and the SSD Monitoring System measures the distance between the X-ray generator and the patient to maintain beam accuracy.

[0058] The measured data is managed and output by the data management unit (140) based on the monitored data. In particular, the data management unit (140) analyzes the dose data collected from the dose monitoring unit, evaluates the treatment effect for each patient, and controls the output. The dose monitoring unit (130) according to one embodiment ensures the safety of treatment and operates in an integrated manner with the control unit (150). In addition, the data management unit (140) stores the patient's treatment data and dose data and configures a database so that it can be reused as data required for follow-up treatment.

[0059] The dose monitoring unit (130) according to one embodiment may use a feedback control algorithm to optimize the dose and energy intensity of the investigated pulse beam for each patient.

[0060] In particular, the dose monitoring unit (130) collects data by communicating with the Dose Rate Monitoring System and the SSD Monitoring System to measure real-time dose information of the patient. The dose monitoring unit (130) uses a feedback control algorithm to optimize the dose and energy intensity of the irradiated pulse beam for each patient.

[0061] A data management unit (140) according to one embodiment collects, stores, analyzes, and outputs data generated in the system.

[0062] According to one embodiment, the data management unit (140) can analyze the dose data collected from the dose monitoring unit, evaluate the treatment effect for each patient, and control the data management unit to output it.

[0063] In addition, the data management unit (140) according to one embodiment can store the patient's treatment data and dose data and configure a database so that it can be reused as data required for follow-up treatment.

[0064] According to one embodiment, the dose monitoring unit (130) analyzes data received to evaluate treatment effects, including lesion size reduction and patient recovery rate. All data is stored in a database and used for follow-up treatment and research. Treatment data is displayed visually and provided to medical staff and patients, increasing reliability. The data management unit serves as a resource for implementing precision medicine.

[0065] The control unit (150) according to one embodiment is a central processing module that comprehensively manages data and transmits commands between the pulse beam information setting unit (110), beam control unit (120), dose monitoring unit (130), and data management unit (140).

[0066] A control unit (150) according to one embodiment maintains the stability of the system by adjusting the data flow between each component.

[0067] It detects abnormal data flows and responds immediately to ensure stability. According to one embodiment, the control unit (150) coordinates each component to achieve optimal performance and is responsible for the overall data flow and commands.

[0068] A pulse beam control system (100) for treating a degenerative brain disease according to an embodiment of the present invention starts when a pulse beam information setting unit (110) sets pulse beam information according to a patient's treatment plan.

[0069] The pulse beam information setting unit (110) automatically calculates and sets the pulse beam information based on treatment plan data transmitted from an external system.

[0070] The control unit (150) transmits this information to the beam control unit (120) to control the X-ray generator. The beam control unit (120) adjusts the physical characteristics of the beam based on the set information and performs treatment. The dose monitoring unit (130) measures the dose and energy of the irradiated beam in real time and transmits the data to the control unit (150).

[0071] The beam control unit (120) provides an optimized irradiation angle and energy distribution to a patient's body part through a multi-gantry structure. In addition, the beam control unit (120) synchronizes the irradiation timing of pulse beams generated from each X-ray generator and irradiates them in parallel or serially.

[0072] The data management unit (140) stores the collected data, evaluates the treatment effectiveness, and utilizes it for follow-up treatment. The pulse beam control system (100) for treating degenerative brain diseases according to one embodiment supports customized, precise treatment of degenerative brain diseases and is designed to maximize treatment effectiveness and safety.

[0073] Figure 2a is a drawing (210) showing the results showing that there is no statistical significance in the effect of reducing Aβ plaques when applying continuous beam (KLDR).

[0074] Figure 2a shows that there is no statistical significance in the effect of reducing the intensity of Aβ plaques when continuous beam (KLDR, Kilovoltage Low-Dose Radiation) is applied to an Alzheimer's disease animal model.

[0075] The X-axis divides the experimental groups into four groups, and each group follows the following treatment conditions.

[0076] The first group is a control group that received neither radiation nor drug administration, including KLDR-naïve (-) and ATC108-naïve (-). This is based on the untreated state in an animal model of Alzheimer's disease.

[0077] The second group was treated with 110 kV continuous beam radiation (KLDR) but not with ATC108 (KLDR+) or with KLDR-only radiation (ATC108-only). This was to evaluate the effect of radiation alone.

[0078] The third group was not exposed to radiation, but was administered the drug ATC108 alone (KLDR-free (-) and ATC108-treated (+)). This was to confirm the effect of the drug alone.

[0079] The fourth group was a group that combined continuous beam radiation (KLDR) and the drug ATC108, with KLDR applied (+) and ATC108 applied (+). This condition was used to evaluate the interaction and combined effect of radiation and the drug.

[0080] The Y-axis quantitatively represents the intensity of Aβ plaques. This reflects the relative concentration of Aβ plaques within brain tissue and is an important indicator for indirectly assessing the progression of Alzheimer's disease. Each bar graph represents the mean of the experimental group, and the error bars represent the standard error of the mean (SEM), which reflects the variability of the data.

[0081] The radiation used was a 110 kV continuous beam (KLDR), and the radiation intensity was set at 0.6 Gy. Radiation exposure was performed twice a week for a total of five sessions, resulting in a cumulative radiation dose of 3 Gy.

[0082] Continuous beam radiation (KLDR) delivers consistent radiation intensity and duration. Unlike pulsed beam radiation (PKLDR), it continuously delivers energy without interruption. The drug ATC108 is a new drug candidate being developed for the treatment of Alzheimer's disease, and is expected to reduce Aβ plaques and have anti-inflammatory effects. The concentration and dose of the administered drug were maintained constant according to the experimental design.

[0083] The highest Aβ plaque intensity was observed in the control group, which received neither continuous beam nor drug treatment. This reflects the progression of Alzheimer's disease in the untreated group.

[0084] In the KLDR group alone, the intensity of Aβ plaques was lower than that of the control group when continuous beam was applied alone, but statistical significance (NS, Not Significant) was not achieved.

[0085] This suggests that the single application of continuous beam therapy has a limited effect on reducing Aβ plaques. Aβ plaque intensity was also reduced in the group administered with the drug ATC108 alone, but this did not reach statistical significance (NS). This demonstrates that the drug's effect alone is limited.

[0086] The group receiving a combination of KLDR and ATC108 showed the lowest Aβ plaque intensity, but statistical significance was not achieved. While the combined effect induced a greater reduction than either treatment alone, it is insufficient to demonstrate a substantial therapeutic effect.

[0087] Figure 2a shows the results of quantitatively evaluating the effects of KLDR-type radiation alone, drug alone, and combined application on reducing Aβ plaques in an animal model of Alzheimer's disease.

[0088] The experimental results showed that continuous beam (KLDR) induced Aβ plaque reduction, but did not achieve statistical significance, suggesting limited therapeutic efficacy. This suggests that continuous beam therapy alone is not sufficient for the treatment of Alzheimer's disease and that more effective treatment methods are needed. This experiment highlights the limitations of continuous beam therapy and supports the possibility that pulsed beam therapy (PKLDR) may be more effective. Previous studies have shown that pulsed beam therapy not only reduces Aβ plaques but also exhibits superior anti-inflammatory effects and improves disease markers. Therefore, the results of this experiment emphasize the need for a transition to pulsed beam therapy. Future studies should directly compare KLDR and PKLDR to further evaluate the therapeutic effects of the two methods. Furthermore, it is necessary to adjust the concentration and dose of ATC108 to explore the optimal conditions for monotherapy or combination therapy.

[0089] KLDR stands for Continuous Kilovoltage Low-Dose Radiation, and ATC108 is a drug candidate for the treatment of Alzheimer's disease. Aβ plaques represent the intensity of beta-amyloid plaques, a pathological hallmark of Alzheimer's disease, and NS (Not Significant) indicates no statistical significance. Error bars represent the standard error of the data for each experimental group. These results clearly demonstrate the limited therapeutic effect of KLDR and emphasize the need for more effective approaches to reduce Aβ plaques.

[0090] Figure 2b is a drawing (210) showing the results showing that the effect of reducing Aβ plaques is statistically significant when applying pulsed beam (PKLDR).

[0091] Figure 2b is a diagram showing that pulsed beam (PKLDR, Pulsed Kilovoltage Low-Dose Radiation) has a statistically significant effect in reducing the intensity of Aβ plaques in an animal model of Alzheimer's disease.

[0092] This study was designed to evaluate the effects of PKLDR radiation alone, alone, and in combination on reducing Aβ plaques, a pathological hallmark of Alzheimer's disease. The results demonstrated the superiority of PKLDR over conventional continuous beam (KLDR) radiation, and quantitatively confirmed the efficacy of its combination with the drug ATC108.

[0093] The X-axis of Figure 2b was composed by dividing the experimental group into four groups.

[0094] The first group, PKLDR-naïve (-) and ATC108-naïve (-), is a control group that received neither radiation nor medication. This represents the progression of Alzheimer's disease in the absence of treatment.

[0095] The second group was the group that received pulsed beam (PKLDR) alone, with PKLDR applied (+) and ATC108 not applied (-). This group is important in confirming the potential improvement in therapeutic efficacy of the PKLDR method compared to the existing continuous beam (KLDR).

[0096] The third group was the group administered only ATC108, with PKLDR not applied (-) and ATC108 applied (+). This was a condition for evaluating the independent therapeutic effect of the drug.

[0097] The fourth group was PKLDR application (+), ATC108 application (+), which combined PKLDR with the drug ATC108. This was designed to evaluate the interaction and combined effects of radiation and the drug.

[0098] The Y-axis quantitatively represents the intensity of Aβ plaques, which indicates the progression of Alzheimer's disease. Plaque intensity reflects the relative concentration of beta-amyloid plaques in brain tissue and is a key indicator of Alzheimer's disease pathology.

[0099] The bar graph represents the mean for each experimental group, and the error bars represent the standard error, which reflects the variability of the data. Statistical significance is indicated in the figure with an asterisk (), indicating a significant difference at the p < 0.01 level. This increases the reliability of the experimental results.

[0100] The pulsed beam (PKLDR) was set to 110 kV energy, and 0.2 Gy was applied in each irradiation. The radiation exposure was divided into three subfractions, with an interval of 3 minutes between each irradiation.

[0101] This pulsed beam irradiation was performed twice a week for a total of five sessions, resulting in a total cumulative radiation dose of 3 Gy. The PKLDR method minimizes tissue damage and maximizes radiation efficacy by dividing the radiation into short bursts.

[0102] This is a key difference from continuous beam radiotherapy (KLDR). ATC108 is a drug candidate developed for the treatment of Alzheimer's disease, targeting Aβ plaque reduction and anti-inflammatory effects. The drug was administered at a consistent concentration and dose according to the experimental design, and can be combined with radiation to maximize plaque reduction effects.

[0103] The control group, which received neither radiation nor medication, exhibited the highest Aβ plaque intensity, reflecting the persistence of Alzheimer's disease pathology in the absence of treatment.

[0104] In the group receiving pulsed beam (PKLDR) alone, Aβ plaque intensity was significantly reduced compared to the control group (p < 0.01). This suggests that the PKLDR method may improve the efficacy of radiotherapy compared to continuous beam (KLDR) and demonstrates that it can induce plaque reduction while minimizing tissue damage.

[0105] Even in the group administered with the drug ATC108 alone, Aβ plaque intensity was significantly reduced compared to the control group (p < 0.01). This indicates that the drug has a potential therapeutic effect that can independently induce Aβ plaque reduction without radiation.

[0106] The group receiving combined PKLDR and ATC108 treatment showed the lowest Aβ plaque intensity among all experimental groups. Combined treatment showed a greater therapeutic effect than either treatment alone, demonstrating a statistically significant reduction in plaque reduction (p < 0.01).

[0107] This suggests that PKLDR and the drug have complementary effects, suggesting that combined therapy holds significant promise in the treatment of Alzheimer's disease.

[0108] Figure 2b visually presents the results of a quantitative evaluation of the effects of radiation alone, drug alone, and combined application of the PKLDR method on Aβ plaque reduction.

[0109] The experimental results showed that pulsed beam (PKLDR) was more effective in reducing Aβ plaques than continuous beam (KLDR), with statistical significance. This suggests that fractionated radiation can minimize tissue damage and maximize therapeutic efficacy. ATC108 can induce Aβ plaque reduction without radiation and plays a significant role in pathological improvement. The combination of pulsed beam and drug treatment showed greater plaque reduction than either treatment alone, demonstrating that the interaction between radiation and drugs is a promising strategy for the treatment of Alzheimer's disease.

[0110] PKLDR stands for Pulsed Kilovoltage Low-Dose Radiation, a pulsed beam method that minimizes tissue damage while maximizing radiation efficacy. ATC108 is a drug candidate for the treatment of Alzheimer's disease, expected to reduce Aβ plaques and have anti-inflammatory effects.

[0111] Aβ plaques are beta-amyloid plaques and are a key pathological feature of Alzheimer's disease. A p < 0.01 value indicates a highly statistically significant result. Error bars represent the standard error of the data, indicating variability. These results demonstrate that PKLDR is a superior treatment option for Alzheimer's disease compared to the existing KLDR approach, highlighting the therapeutic synergy of drug combinations.

[0112] Figure 3 is a drawing (300) showing that in a live imaging experiment, the expression level of M2-type microglia (CD206, anti-inflammatory action) significantly increases when a pulsed beam (PKLDR) is applied.

[0113] Figure 3 shows the results of evaluating the inflammatory response regulation and anti-inflammatory effect by measuring the change in the expression level of M2-type microglia (CD206) in a live imaging experiment using pulsed beam (PKLDR, Pulsed Kilovoltage Low-Dose Radiation).

[0114] M2-type microglia are cells that play a role in suppressing inflammation and promoting tissue repair. This study visually demonstrates the effect of PKLDR application on the expression of these cells. The experiment was designed to analyze the effect of PKLDR on modulating the inflammatory environment and to track changes over time.

[0115] In Figure 3, the difference in expression levels between the control group (Sham) and the PKLDR application group at three time points: Day 1, Day 3, and Week 8 is compared.

[0116] The X-axis is divided into Sham and PKLDR. Sham is the non-irradiated group, representing the natural level of M2-type microglia expression.

[0117] PKLDR is a group that applied pulsed beam (PKLDR) radiation, and evaluates changes in M2-type microglia expression and anti-inflammatory effects after radiation exposure. The Y-axis quantitatively represents the expression level of M2-type microglia (CD206), and the unit is expression level.

[0118] Expression level reflects the degree of cell activation and is an important indicator for evaluating the strength of inflammation control and anti-inflammatory response.

[0119] Figure 3 compares the results at three time points.

[0120] Day 1 evaluates the initial effects of radiation therapy, measuring the first day after the initial treatment. Day 3 evaluates the initial anti-inflammatory effects, measuring the third day after the initial treatment. Week 8 evaluates the long-term effects, measuring the eighth week after the initial treatment.

[0121] The bar graph represents the mean for each experimental group, and the error bars represent the standard error, which reflects the variability of the data. Statistical significance is indicated by the p-value, with p < 0.05 indicating a significant difference and used to verify the effectiveness of PKLDR.

[0122] Under the PKLDR application conditions, the radiation energy was set to 110 kV, and the radiation was divided into three sub-fractions of 0.2 Gy each.

[0123] The interval between each irradiation was set to 3 minutes, and the procedure was performed twice a week for a total of five sessions. The PKLDR method effectively controls inflammation while minimizing tissue damage by dividing the irradiation into pulses. The sham condition, which did not receive irradiation, served as a control group to assess the natural expression of M2-type microglia.

[0124] On Day 1, the expression of M2-type microglia in the PKLDR group significantly increased compared to the control group (Sham) (p = 0.0422). This suggests that PKLDR regulates the inflammatory environment and induces an early anti-inflammatory response. The rapid increase in expression is interpreted as a result of radiation activating M2-type microglia, stimulating their transition to an anti-inflammatory state. In contrast, expression levels remained low in the Sham group, likely due to the absence of radiation or external stimuli.

[0125] On Day 3, the expression level of M2-type microglia in the PKLDR group increased slightly compared to Day 1, but the difference from the control group did not reach statistical significance (p = 0.0551).

[0126] This suggests that the initial effect persists, but suggests that natural healing or changes in the inflammatory environment may have contributed to the diminished effect. In the sham group, expression levels remained low, and the difference with the PKLDR group tended to decrease.

[0127] In Week 8, the expression level in the PKLDR group decreased, narrowing the difference from the control group. However, statistical significance was not achieved (p = 0.1181). This suggests that the long-term anti-inflammatory effect of PKLDR may have diminished, or that the difference in expression level may have decreased due to changes in the natural immune environment. In the sham group, expression level remained similar to the initial level.

[0128] PKLDR induced an early anti-inflammatory effect, significantly increasing the expression of M2-type microglia on Day 1. This demonstrates that radiation is effective in modulating the inflammatory environment and promoting an anti-inflammatory state. Although the expression level in the PKLDR group was maintained on Day 3, the difference compared to the control group tended to decrease. This suggests that while PKLDR maintains its initial effect, it may be influenced by changes in the inflammatory environment or natural healing processes over time.

[0129] At Week 8, the effect of PKLDR was diminished, and the difference compared to the control group was not significant. This suggests that additional radiotherapy or a combination treatment strategy may be necessary to maximize the long-term effect of PKLDR.

[0130] PKLDR uses short bursts of radiation to minimize tissue damage and maximize the effectiveness of regulating the inflammatory response. M2-type microglia (CD206) are anti-inflammatory microglia that suppress inflammation and promote tissue repair, playing a key role in regulating the inflammatory environment.

[0131] Sham represents the non-irradiated control group, representing the natural expression state of M2-type microglia. The p-value indicates statistical significance, with p < 0.05 indicating a significant difference. Error bars represent the standard error of the data, indicating variability.

[0132] PKLDR was effective in regulating the early inflammatory response and significantly increased the expression of M2-type microglia at Day 1.

[0133] This suggests that the PKLDR approach is a promising method for inducing inflammation suppression and anti-inflammatory activation in the treatment of neurodegenerative diseases. However, a gradual decline in efficacy was observed on Day 3 and Week 8, suggesting the need for additional strategies, such as repeated PKLDR administration or combination therapy, to maximize long-term effects.

[0134] Figure 4 is a drawing (400) showing that in a live imaging experiment, the expression levels of disease markers Aβ42 and tau are significantly reduced when a pulsed beam (PKLDR) is applied.

[0135] Figure 4 is a diagram showing the results of evaluating the effect of pulsed beam (PKLDR, Pulsed Kilovoltage Low-Dose Radiation) on reducing the expression of Aβ42 and tau proteins, which are disease markers, in an Alzheimer's disease animal model over time.

[0136] Aβ42 and tau are key indicators reflecting the pathological progression of Alzheimer's disease, and a decrease in the expression of these substances is considered an important measure for evaluating disease suppression and therapeutic effects.

[0137] The experiment in Fig. 4 was designed to analyze how the PKLDR method changes the expression of these pathological markers, and Fig. 4 compares the difference in expression levels between the control group (Sham) and the PKLDR application group at two time points, Week 4 and Week 12, to verify the short-term and long-term effects of PKLDR.

[0138] The X-axis shows two experimental conditions, Sham and PKLDR, and shows the expression results for Aβ42 and tau proteins at Week 4 and Week 12, respectively.

[0139] The Sham group, which was not irradiated, serves as a reference group for assessing the natural expression of Aβ42 and tau. The PKLDR group is used to assess the effects of irradiation on the expression of disease markers. The Y-axis quantitatively represents the expression levels of Aβ42 and tau, with the unit being expression level. Expression levels directly reflect the pathological state, and a decrease in these substances indicates inhibition of disease progression and therapeutic effects.

[0140] The bar graph represents the mean for each experimental group, and the error bars show the standard error, which reflects the variability of the data. Statistical significance is indicated by the p-value, with p < 0.05 indicating a significant difference. Aβ42 showed a significant decrease at Week 12 (p = 0.0439), and tau showed a statistically highly significant decrease at Week 12 (p = 0.0001).

[0141] PKLDR was administered at a radiation energy of 110 kV, divided into three subfractions of 0.2 Gy each. The interval between each dose was set to 3 minutes, and the treatment was performed twice a week for a total of five sessions.

[0142] PKLDR minimizes tissue damage and maximizes therapeutic efficacy by dividing radiation into pulses. The sham group, a non-irradiated control group, was used to compare and analyze the therapeutic effects of PKLDR based on the natural expression levels of Aβ42 and tau.

[0143] At Week 4, Aβ42 expression was lower in the PKLDR group than in the control group, but this difference did not reach statistical significance (p = 0.1027). Tau expression was also slightly lower in the PKLDR group than in the control group, but this difference did not reach statistical significance (p = 0.1016). This indicates that the initial effect of PKLDR was not evident at Week 4.

[0144] At Week 12, Aβ42 expression was significantly reduced in the PKLDR group compared to the control group, achieving statistical significance (p = 0.0439). Tau expression was also significantly reduced in the PKLDR group compared to the control group, demonstrating a statistically significant difference (p = 0.0001). This indicates that PKLDR is effective in suppressing Aβ42 and tau protein expression in the long term.

[0145] PKLDR significantly reduced the expression of Aβ42 and tau, key pathological markers of Alzheimer's disease, at Week 12. This demonstrates that PKLDR inhibits the progression of Alzheimer's disease and is an effective approach for disease treatment.

[0146] While the effect of PKLDR was not evident in Week 4, a significant decrease in expression was observed in Week 12. This suggests that PKLDR requires some time to exert its therapeutic effect and may exhibit greater long-term effects. PKLDR is superior to conventional continuous beam (KLDR) methods in suppressing disease markers and is considered a promising radiation technique for the treatment of Alzheimer's disease.

[0147] PKLDR is a pulsed, low-dose radiation technology that maximizes therapeutic efficacy while minimizing tissue damage. Aβ42 and tau are key disease markers reflecting the pathological progression of Alzheimer's disease, and a decrease in their expression indicates a disease-suppressing effect.

[0148] Sham is a non-irradiated control group, used as a reference group to assess the natural state of Aβ42 and tau expression. The p-value indicates statistical significance, with p < 0.05 indicating a significant difference. Error bars represent the standard error of the data, indicating variability, and enhance the reliability of each experimental group.

[0149] PKLDR significantly reduced the expression of disease markers Aβ42 and tau, demonstrating its effectiveness in inhibiting the progression of Alzheimer's disease. The statistically significant results at Week 12, in particular, support the long-term therapeutic potential of PKLDR.

[0150] Figure 5 is a drawing (500) showing that inflammation markers (TNF-α, IL-1β), recovery genes (RSPO1), and dopamine pathways (VMAT2, DAT) significantly increase when pulsed beam (PKLDR) is applied.

[0151] Figure 5 is a drawing showing the results of a quantitative evaluation of the effect of pulsed beam (PKLDR, Pulsed Kilovoltage Low-Dose Radiation) on changes in the expression of neuroinflammatory markers (TNF-α, IL-1β, recovery gene (RSPO1), and dopamine pathway proteins (VMAT2, DAT).

[0152] The experiment in Fig. 5 was designed to determine whether PKLDR is effective in suppressing inflammatory responses and activating neuronal recovery and dopaminergic pathways using a Parkinson's disease animal model (MPTP-induced model).

[0153] TNF-α and IL-1β are major markers that induce neuroinflammation, and decreased expression indicates relief of inflammation and inhibition of tissue damage.

[0154] RSPO1 is an important repair gene involved in tissue repair and regeneration, and VMAT2 and DAT are major proteins responsible for dopamine storage and transport, and increased expression of these indicates restoration of dopamine pathway function.

[0155] Figure 5 quantitatively evaluates the effect of PKLDR by comparing the difference in expression between two radiation dose conditions of PKLDR (4 cGy and 50 cGy) and the control group (MPTP).

[0156] The X-axis represents the experimental conditions, the control group (MPTP) is the group that induced dopamine neuron damage, and the effect of PKLDR is compared based on the natural expression level of each marker.

[0157] PKLDR 4 cGy is a group for analyzing the effect of radiation on inflammatory response and recovery gene expression under low-dose conditions, and PKLDR 50 cGy is a group for evaluating the effect under high-dose conditions.

[0158] The Y-axis quantitatively represents the relative mRNA expression level of each marker (TNF-α, IL-1β, RSPO1, VMAT2, DAT), expressing the percentage increase or decrease compared to the reference group. Expression level is an important indicator for evaluating the degree of inflammation suppression, tissue repair, and dopaminergic pathway activation.

[0159] The bar graph represents the mean for each experimental group, and the error bars indicate the standard error. Statistical significance is indicated by the p-value, with p < 0.05 indicating a significant difference. In Figure 5, an asterisk (*) indicates a significant result, and "NS" indicates a statistically insignificant result.

[0160] Under PKLDR conditions, the radiation energy was set to 110 kV, and the radiation intensity was divided into two conditions of 4 cGy and 50 cGy.

[0161]

[0162] Radiation was administered in short pulses, with an interval of 3 minutes between each pulse.

[0163] The study was conducted twice a week for a total of five sessions. PKLDR is a radiation technique that maximizes anti-inflammatory effects while minimizing tissue damage. The control group (MPTP), a neurotoxin that induces dopamine neuron damage, leading to neuroinflammation and dysfunction, was designated as the reference group for evaluating the therapeutic efficacy of PKLDR.

[0164] TNF-α expression was significantly reduced in the PKLDR 4 cGy condition compared to the control group (p < 0.05). This indicates that low-dose PKLDR exerts an anti-inflammatory effect by suppressing major inflammatory substances.

[0165] A decrease in expression was observed under the PKLDR 50 cGy condition, but the difference was not statistically significant. IL-1β expression showed a decreasing trend under both conditions, but the difference was not statistically significant. This suggests that PKLDR has a relatively minimal effect on IL-1β suppression.

[0166] RSPO1 expression levels tended to increase under the PKLDR 4 cGy condition, but this did not reach statistical significance. This suggests that low-dose PKLDR may promote neural tissue repair. Increased expression levels were also observed under the PKLDR 50 cGy condition, but this did not reach statistical significance.

[0167] VMAT2 expression was significantly increased in the PKLDR 4 cGy condition compared to the control group (p < 0.05). This suggests that low-dose PKLDR can promote the recovery of neuronal function related to dopamine storage.

[0168] An increase in expression was observed under the 50 cGy PKLDR condition, but the difference was not statistically significant. DAT expression tended to increase under both conditions, but the difference was not statistically significant. This suggests that PKLDR may have limited effects on dopamine transporter pathway activation.

[0169] PKLDR 4 cGy significantly reduced TNF-α expression, demonstrating its effectiveness in suppressing neuroinflammatory responses. This suggests that PKLDR may be an important therapeutic approach in neuroinflammatory diseases such as Parkinson's disease. The trend toward increased RSPO1 expression suggests that PKLDR may promote neural tissue repair and regeneration.

[0170] Although statistical significance was not achieved, activation of recovery genes is considered an important indicator for assessing long-term treatment efficacy. The increased VMAT2 expression confirmed that 4 cGy of PKLDR can promote the recovery of neuronal function related to dopamine storage. This supports the therapeutic potential of PKLDR in Parkinson's disease, which is associated with dopamine deficiency.

[0171] PKLDR has been shown to be effective in suppressing neuroinflammation and restoring neuronal function by suppressing key inflammatory markers such as TNF-α and significantly increasing the expression of dopaminergic pathway proteins such as VMAT2.

[0172] The trend toward increased expression of RSPO1 and DAT suggests that PKLDR may play a positive role in neural tissue repair and dopaminergic pathway activation. PKLDR technology is considered an innovative therapeutic approach that simultaneously targets inflammation suppression and neural repair, and may play a key role in the treatment of neurodegenerative diseases.

[0173] FIG. 6 is a drawing (600) showing a pulse beam precisely controlled by the present invention.

[0174] Figure 6 is a drawing visually showing various duty cycle types of pulse beams precisely controlled based on pulsed beam (PKLDR, Pulsed Kilovoltage Low-Dose Radiation) technology.

[0175] Figure 6 shows the process of implementing optimized radiation irradiation according to the treatment purpose and individual patient characteristics by changing the ratio of pulse width length and irradiation time through duty cycle control, which is a core technology of the pulse beam control system.

[0176] Duty Cycle is defined as the ratio between the 'On' time of the pulse and the total cycle, and plays an important role in regulating the biological stimulation effect and tissue response of the pulsed beam.

[0177] Figure 6 includes three examples of duty cycles of 50%, 75%, and 25%, and specifically shows the changes in pulse width and irradiance ratio according to each duty cycle.

[0178] A 50% Duty Cycle means that the pulse beam is set to the 'On' and 'Off' states at equal rates, and radiation is irradiated for only half of the total irradiation time.

[0179] It is suitable for maintaining the balance between biological stimulation effect and tissue damage, and can be used to ensure safety and efficacy in the early stages of treatment of Alzheimer's disease or Parkinson's disease.

[0180] The 75% Duty Cycle setting means the pulsed beam remains "on" for 75% of the entire cycle, extending the radiation exposure time and providing a more intense stimulation effect. This setting can be applied to patients with advanced disease or situations requiring higher treatment intensities. However, the high exposure rate may increase the risk of tissue damage, necessitating precise control tailored to individual patient characteristics.

[0181] The 25% Duty Cycle means the pulsed beam is "on" for 25% of the full cycle, providing relatively low radiation exposure. This setting minimizes tissue damage while ensuring long-term therapeutic effects, making it suitable for sensitive patients or for early-stage preventative treatment.

[0182] The pulsed beam control system precisely adjusts tube voltage and tube current under each duty cycle condition to optimize radiation energy intensity and dose. The pulsed beam on / off cycle is finely adjusted to control pulse width, cycle, and irradiation frequency, enabling customization based on biological response mechanisms and therapeutic effects. Pulsed beams are delivered serially or in parallel through multiple ports, providing optimized energy distribution and irradiation angles for each patient area.

[0183] Duty cycle adjustments can achieve maximum therapeutic efficacy with minimal radiation dose. This enables personalized treatment for each patient, ensuring both safety and efficacy. This technology can be applied to the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as inflammatory diseases and those requiring tissue regeneration. Each duty cycle condition is optimized to modulate various biological responses, including inflammation suppression, tissue repair, and nerve regeneration.

[0184] Figure 6 visually illustrates the key control capabilities of pulsed beam control technology, highlighting the potential of radiation protocols to maximize therapeutic efficacy.

[0185] Figure 7 is a drawing (700) showing an application field of the present invention.

[0186] Figure 7 visually illustrates an application example of precision radiation irradiation using a multi-gantry structure designed based on pulsed beam (PKLDR, Pulsed Kilovoltage Low-Dose Radiation) technology.

[0187] Figure 7 illustrates a method for delivering personalized treatment by irradiating the target area with optimized radiation using various pulsed beam emitters. The system precisely controls the irradiation angle and energy intensity, and is designed to maximize the therapeutic effect on the target tissue while minimizing damage to surrounding tissue.

[0188] Figure 7 shows four pulse beam emitters arranged in a manner designed to irradiate radiation around the patient.

[0189] Each emitter is independently controllable, adjusting the intensity and direction of the radiation depending on the location, size, and disease state of the target tissue. These emitters work together to deliver radiation from multiple angles, making them particularly effective when targeting atypical lesions or deep tissue.

[0190] The patient is positioned at the center of the gantry structure and held in a stable position. The system adjusts the direction and energy of the radiation beam, taking into account the patient's anatomy and pathological characteristics. The system is designed to ensure that the patient's head and body are precisely positioned within the radiation field, enabling treatment of sensitive areas such as the brain and nerve tissue.

[0191] The multi-gantry design optimizes the positioning of each pulse beam emitter to precisely deliver radiation to a specific area of ​​the patient.

[0192] The system of Fig. 7 maintains a uniform irradiation range and can irradiate multiple parts of the patient's body simultaneously or sequentially.

[0193] Each pulsed beam emitter independently adjusts tube voltage and tube current to optimize the amount and energy of radiation delivered. Pulse width, irradiation cycle, and radiation duration can be precisely controlled to achieve specific treatment goals.

[0194] A real-time dose monitoring system monitors the radiation dose during the treatment and adjusts it immediately if necessary. The multi-port design delivers radiation from multiple directions, ensuring that the radiation is focused on the target tissue. For example, when treating a specific lesion in the brain, four emitters deliver radiation from different angles, concentrating the radiation on the lesion and minimizing exposure to surrounding normal tissue.

[0195] The system in Figure 7 establishes a radiation treatment plan based on medical images, such as MRI and CT data, of the patient. It analyzes the patient's body structure, lesion location, and tissue sensitivity to individually optimize pulsed beam treatment conditions (radiation dose, treatment angle, and treatment time).

[0196] Pulsed beam control systems are effective in suppressing neuroinflammation and reducing pathological markers (Aβ plaques, tau protein) in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

[0197] It enables precise treatment of sensitive brain tissue, focusing radiation on the affected area to minimize damage to surrounding tissue. Beyond brain disease, it can be used to treat a variety of conditions, including arthritis, inflammatory diseases, and cancer. Using low-dose radiation, it modulates inflammatory responses and promotes tissue regeneration.

[0198] The multi-gantry structure and real-time control system enable maximum therapeutic efficacy within a short period of time. This improves the patient's treatment experience and minimizes side effects from radiation exposure.

[0199] Figure 7 visually illustrates how a pulsed beam control system utilizes a multi-gantry structure to precisely perform radiotherapy.

[0200] Figure 8 is a drawing (800) explaining an operating system according to one embodiment.

[0201] Figure 8 shows a detailed operational schematic diagram of a system implementing pulsed beam (PKLDR, Pulsed Kilovoltage Low-Dose Radiation) technology.

[0202] Figure 8 visually illustrates the architecture of a multi-control system designed for various medical applications, including treatment of degenerative brain diseases, and the signal flow between each component.

[0203] The Radiation Treatment Planning System establishes a radiation treatment plan, including treatment area, irradiation intensity, and irradiation angle, based on the patient's medical images, such as MRI and CT.

[0204] The Radiation Treatment Planning System transmits data in DICOM format to a PC (console), and the PC controls the X-ray generator and other components based on this data.

[0205] The PC serves as the central control unit of this system, responsible for communication and control with all components. It receives DICOM data and exchanges signals with key components such as the X-ray Generator, Dose Rate Monitoring System, SSD Monitoring System, and Couch System. The PC controls tube voltage, tube current, pulse width, irradiation cycle, and irradiation timing in real time, enabling personalized treatment.

[0206] The Dose Rate Monitoring System measures the radiation dose delivered to the patient in real time during radiation therapy. This data is transmitted to a PC, allowing for immediate adjustments to radiation intensity and duration as needed. This plays a crucial role in maximizing radiation safety and therapeutic effectiveness.

[0207] The SSD Monitoring System measures the Source-to-Surface Distance (SSD) between the X-ray generator and the patient. This distance data is transmitted to a PC and used to optimize the radiation angle and intensity, ensuring that the radiation reaches the target tissue accurately.

[0208] The X-ray generator generates radiation based on signals transmitted from a PC. Each generator can independently adjust tube voltage, tube current, and pulse width, and operates in series or parallel through multiple ports. These generators deliver radiation in a multi-gantry configuration, enabling precise and efficient treatment.

[0209] The Couch System and Gantry Control Panel adjust the patient's position and stabilize the patient, ensuring that the radiation reaches the target tissue accurately. The Gantry Control Panel precisely adjusts the patient's treatment position, and the Light Button provides visual confirmation of the treatment area.

[0210] The Control Panel comprehensively manages signals from the X-ray Generator and Gantry Control Panel, supervising the entire radiation treatment process. This allows medical staff to easily operate the system.

[0211] Main Power supplies power to the entire system and maintains power signals to ensure smooth operation of each component.

[0212] The system of Fig. 8 covers the entire process from establishing a radiation treatment plan to radiation irradiation.

[0213] Treatment plans generated by the Radiation Treatment Planning System are transmitted to a PC, which then comprehensively controls all components based on this data. The X-ray Generator generates radiation according to commands received from the PC, and the Dose Rate Monitoring System and SSD Monitoring System provide real-time data to detect radiation dose and distance.

[0214] The Couch System and Gantry Control Panel optimize the patient's position and irradiation angle, and the Control Panel monitors the operating status of the entire system.

[0215] The schematic diagram of Figure 8 can provide high precision and safety in various medical applications, including treatment of degenerative brain diseases.

[0216] Integrated signal flow between each component enables patient-tailored treatment, achieving maximum therapeutic effect with minimal radiation, and minimizing adverse effects from radiation exposure through multi-port control and real-time data feedback.

[0217] This system can be expanded to various medical fields such as cancer treatment and inflammatory diseases as well as degenerative diseases.

[0218] For example, the Radiation Treatment Planning System of Fig. 8 corresponds to a defined pulse beam information setting unit.

[0219] A radiation treatment plan is developed based on the patient's medical imaging data. This treatment plan is converted to DICOM format and transmitted to a PC (console). This provides basic data for adjusting radiation generator parameters, enabling personalized treatment.

[0220] The X-Ray Generator in Figure 8 is matched with a defined beam control unit and consists of four independent radiation generators. It optimizes the beam quantity and energy of radiation by adjusting the tube voltage and tube current according to parameters received from the PC (Console), and adjusts the radiation irradiation cycle, pulse width, and irradiation time in real time. This allows for precise control of the direction and intensity of radiation, optimizing treatment of the lesion site and minimizing the impact on surrounding normal tissue.

[0221] The Dose Rate Monitoring System in Figure 8 corresponds to a defined dose monitoring unit and measures the radiation dose delivered to the patient in real time during treatment. The measured data is transmitted to a PC (console), allowing for the identification of excess or insufficient dose levels and immediate adjustments. This system continuously monitors radiation exposure, ensuring patient safety and maximizing treatment efficiency.

[0222] The PC (Console) communicates with the radiation generator, dose monitoring system, and SSD monitoring system based on treatment plan data received from the Radiation Treatment Planning System, and comprehensively manages the treatment process.

[0223] All real-time data is collected, processed, and stored, and radiation parameters are adjusted as needed to immediately resolve any errors that may arise during the treatment process. This serves as a central hub that enhances treatment stability and efficiency, enabling integrated operation of the entire system.

[0224] The PC (Console) functions as a defined control unit alongside the data management unit, coordinating communication between components and storing data generated during radiation therapy in real time. Based on the collected data, it controls the tube voltage, tube current, pulse width, and other parameters of the radiation generator. This unit is responsible for overall control and management of the treatment, maximizing system stability and therapeutic efficacy.

[0225] The SSD Monitoring System in Figure 8 maintains radiation accuracy by measuring the distance (SSD) between the patient and the radiation generator in real time. The measured data is transmitted to a PC (Console) to adjust the radiation position and intensity, and any movement of the patient during treatment is immediately detected. This ensures radiation accuracy and prevents unnecessary radiation exposure.

[0226] The Couch System and Gantry Control Panel in Figure 8 are devices that secure the patient's position and control radiation delivery. They stably secure the patient, adjust the angle and direction of radiation delivery, and enhance treatment precision. The Light Button and Laser Button confirm and determine the patient's precise position during the treatment preparation phase. They minimize patient movement during the radiation delivery process and ensure accurate delivery of radiation to the target area.

[0227] The treatment plan created in the Radiation Treatment Planning System is transmitted to the PC (Console) in DICOM format.

[0228] The PC (Console) analyzes data, communicates with the X-ray generator, dose monitoring system, and SSD monitoring system, and comprehensively manages the treatment process. The X-ray generator delivers radiation according to set parameters, and the Dose Rate Monitoring System and SSD Monitoring System collect data in real time to maintain treatment accuracy. The Couch System and Gantry Control Panel maintain accurate patient positioning and optimize the direction and angle of radiation delivery.

[0229] FIG. 9 is a diagram illustrating an operation method of a pulse beam control system for treating degenerative brain diseases according to one embodiment.

[0230] Figure 9 is a step-by-step diagram illustrating the operation of a pulsed beam control system (PKLDR, Pulsed Kilovoltage Low-Dose Radiation) for the treatment of degenerative brain diseases, detailing the treatment process, including planning, execution, monitoring, and evaluation of radiation therapy. This diagram emphasizes the precision and effectiveness of radiation therapy through its linkage with the components defined in the claims.

[0231] The first step (901) according to one embodiment is to set pulse beam parameters based on the pathological characteristics and treatment goals of the patient being treated. To this end, the pulse number, pulse cycle, pulse beam irradiation angle, and pulse beam energy are set according to the patient's characteristics and treatment goals. This is performed through a treatment planning system (Radiation Treatment Planning System).

[0232] Medical imaging data, such as MRI and CT scans, are analyzed to determine the location, size, and surrounding tissue condition of the lesion. Based on this, the radiation treatment area is determined.

[0233] Pulse frequency refers to the number of times radiation is administered and is optimized to maximize biological response and minimize side effects.

[0234] Pulse frequency provides time for tissue recovery between exposures, while pulse width controls the duration of radiation exposure.

[0235] The angle and direction of the radiation beam are precisely set using a multi-gantry structure, focusing the radiation on the lesion. The set pulse beam information is converted into DICOM format and transmitted to a PC (console).

[0236] The second step (902) is the process of generating and irradiating radiation based on data received from the PC (Console). Based on the set information, the tube voltage, tube current, pulse width, irradiation time, and irradiation point of the multi-port X-ray generator are individually controlled in series or in parallel. The X-ray generator plays a key role.

[0237] It consists of a multi-port X-ray generator, each of which can be controlled independently. The generator irradiates the lesion area with the optimal radiation direction and intensity.

[0238]

[0239] The energy intensity and dose of radiation are adjusted through tube voltage and tube current. Pulse width and cycle are controlled according to the treatment goal, and the timing of the radiation is also precisely managed. The multi-gantry structure utilizes radiation to deliver radiation to the lesion from various angles, minimizing radiation exposure to normal tissue.

[0240] The third step (903) involves real-time monitoring and data storage of radiation delivery status during treatment. This process monitors and stores patient-specific dose information corresponding to the controlled pulse beam in real-time. The Dose Rate Monitoring System (DRS) measures the radiation dose received by the patient during radiation treatment in real-time.

[0241] The measurement data is transmitted to the PC (Console) and compared to the target dose to check for excess or deficiency.

[0242] The SSD Monitoring System (SMS) measures the distance between the radiation source and the patient in real time, maintaining radiation dose accuracy. All real-time data is stored and used for follow-up treatment planning and analysis of treatment effects.

[0243] The final step (904) involves analyzing treatment data to evaluate and document treatment effectiveness. The patient's treatment effectiveness is analyzed and documented based on the stored data. The stored data is then compared and evaluated with dose data and the patient's biological response, which is then reflected in improving the treatment protocol. The analysis results are recorded as treatment data and utilized for future treatment and system optimization.

[0244] The pulse beam control system enables personalized treatment by controlling pulse width, cycle, intensity, and direction in real time. Real-time monitoring minimizes radiation exposure and maximizes therapeutic efficacy.

[0245] For example, the control stage of a multi-port X-ray generator can provide optimized irradiation angles and energy distribution to a patient's body part by using a multi-gantry structure.

[0246] In addition, by using the present invention, radiation can be uniformly distributed even to a complex lesion structure using a multi-gantry structure, and patient-tailored radiation treatment is possible through precise control of pulse beam parameters.

[0247] In addition, stored treatment data can be used to analyze long-term treatment effects and establish improved treatment strategies, and the patient's subtle movements can be corrected in real time to maintain radiation irradiation accuracy.

[0248]

[0249] It can be applied to various diseases, including Alzheimer's disease, Parkinson's disease, tumor treatment, and inflammatory diseases. Figure 9 illustrates step-by-step how the pulse beam control system operates integrated throughout the entire radiation treatment process, detailing the technical configuration that enhances treatment efficacy and safety. The present invention demonstrates its potential as an innovative technology in various medical fields.

[0250]

[0251] The devices described above may be implemented as hardware components, software components, and / or a combination of hardware components and software components. For example, the devices and components described in the embodiments may be implemented using one or more general-purpose computers or special-purpose computers, such as, for example, a processor, a controller, an arithmetic logic unit (ALU), a digital signal processor, a microcomputer, a field programmable array (FPA), a programmable logic unit (PLU), a microprocessor, or any other device capable of executing instructions and responding to them. The processing device may execute an operating system (OS) and one or more software applications running on the operating system. The processing device may also access, store, manipulate, process, and generate data in response to the execution of the software. For ease of understanding, the processing device is sometimes described as being used alone; however, one of ordinary skill in the art will recognize that the processing device may include multiple processing elements and / or multiple types of processing elements. For example, a processing unit may include multiple processors, or a processor and a controller. Other processing configurations, such as parallel processors, are also possible.

[0252] Software may include a computer program, code, instructions, or a combination of one or more of these, which may configure a processing device to perform a desired operation or may, independently or collectively, command the processing device. The software and / or data may be permanently or temporarily embodied in any type of machine, component, physical device, virtual equipment, computer storage medium or device, or transmitted signal wave, for interpretation by the processing device or for providing instructions or data to the processing device. The software may also be distributed over networked computer systems and stored or executed in a distributed manner. The software and data may be stored on one or more computer-readable recording media.

[0253] The method according to the embodiment may be implemented in the form of program commands that can be executed through various computer means and recorded on a computer-readable medium. The computer-readable medium may include program commands, data files, data structures, etc., alone or in combination. The program commands recorded on the medium may be those specially designed and configured for the embodiment or may be those known and available to those skilled in the art of computer software. Examples of the computer-readable recording medium include magnetic media such as hard disks, floppy disks, and magnetic tapes, optical media such as CD-ROMs and DVDs, magneto-optical media such as floptical disks, and hardware devices specially configured to store and execute program commands, such as ROMs, RAMs, and flash memories. Examples of the program commands include not only machine language codes generated by a compiler, but also high-level language codes that can be executed by a computer using an interpreter, etc. The hardware devices described above may be configured to operate as one or more software modules to perform the operations of the embodiment, and vice versa.

[0254] Although the embodiments described above have been described with limited drawings, those skilled in the art will recognize that various modifications and variations can be made based on the above description. For example, appropriate results can still be achieved even if the described techniques are performed in a different order than described, and / or components of the described systems, structures, devices, circuits, etc. are combined or combined in a different manner than described, or are replaced or substituted with other components or equivalents.

[0255] Therefore, other implementations, other embodiments, and equivalents to the claims also fall within the scope of the claims described below.

Claims

1. In a pulse beam control system for treating degenerative brain diseases exclusively for a carbon nanotube X-ray generator, A pulse beam information setting unit that sets pulse beam information including pulse number, pulse cycle, pulse beam irradiation angle, or pulse beam energy according to the patient's characteristics and treatment purpose; A beam control unit that individually controls in series or in parallel at least one of the tube voltage, tube current, pulse width, irradiation time, or irradiation point of a multi-port X-ray generator based on the above-set pulse beam information; A dose monitoring unit that monitors and stores patient-tailored dose information corresponding to the generated pulse beam in real time; A data management unit that manages and outputs patient treatment data based on the above monitored data; A pulse beam control system for treating degenerative brain diseases, characterized by including:

2. In paragraph 1, The above pulse beam information setting unit, A pulse beam control system for treating degenerative brain diseases, characterized in that it automatically calculates and sets the pulse beam information based on treatment plan data transmitted from an external system.

3. In paragraph 1, The above beam control unit, A pulse beam control system for treating degenerative brain diseases, characterized by providing an optimized irradiation angle and energy distribution to a patient's body part through a multi-gantry structure.

4. In paragraph 1, The above dose monitoring unit, A pulse beam control system for treating degenerative brain diseases, characterized in that it collects data by communicating with a Dose Rate Monitoring System and an SSD Monitoring System to measure real-time dose information of a patient.

5. In paragraph 1, The above data management department, A pulse beam control system for treating degenerative brain diseases, characterized in that it analyzes the dose data collected from the dose monitoring unit, evaluates the treatment effect for each patient, and controls the output.

6. In paragraph 1, The above data management department, A pulse beam control system for treating degenerative brain diseases, characterized in that it configures a database to store patient treatment data and dose data and reuse them as data required for follow-up treatment.

7. In paragraph 1, The above beam control unit, A pulse beam control system for treating degenerative brain diseases, characterized in that the irradiation time of pulse beams generated from each X-ray generator is synchronized and irradiated in parallel or serially.

8. In paragraph 1, The above dose monitoring unit, A pulse beam control system for treating degenerative brain diseases, characterized in that it uses a feedback control algorithm to optimize the dose and energy intensity of the investigated pulse beam for each patient.

9. A pulse beam control method for treating degenerative brain diseases, A step of setting the pulse number, pulse cycle, pulse beam irradiation angle, and pulse beam energy according to the patient's characteristics and treatment purpose; A step of individually controlling the tube voltage, tube current, pulse width, irradiation time and irradiation point of a multi-port X-ray generator in series or in parallel based on the above-set information; A step of monitoring and storing patient-tailored dose information corresponding to the above-mentioned controlled pulse beam in real time; and A step of analyzing and recording the patient's treatment effect based on the above stored data. A pulse beam control method for treating degenerative brain diseases, characterized by including:

10. In paragraph 9, The step of setting the pulse number, pulse period, pulse beam irradiation angle and pulse beam energy is: Steps to automatically set based on patient data received from an external system A pulse beam control method for treating degenerative brain diseases, characterized by including:

11. In paragraph 9, The control step of the above multi-port X-ray generator is: A step that provides optimized irradiation angles and energy distribution to the patient's body part using a multi-gantry structure. A pulse beam control method for treating degenerative brain diseases, characterized by including:

Images